Published: July 2013
A new report published by Roots Analysis Private Limited estimates the market for Antibody Drug Conjugates (ADCs) to grow to USD 9 billion annually by 2023. The report provides an extensive study of this emerging market, including detailed sales forecasts of the following eight promising ADCs
3. Inotuzumab Ozogamicin
4. Glembatumumab Vedotin
5. Lorvotuzumab Mertansine
Owing to niche nature of the market, the report provides three scenarios for market forecast. The conservative, base and optimistic scenarios represent three different tracks of market evolution, governed by the success of pipeline drugs. Under the base case, the company forecasts a CAGR of 84% till 2018. The sales are expected to rise steadily from its 2012 size of USD 138 million.
ADCs provide an attractive opportunity for pharmaceutical companies to fill their depleting pipelines. Driven by the availability of monoclonal antibodies targeting various types of cancer, majority of ADCs currently under development are for oncological indications. Some drug developers are now also looking outside the oncology domain. However, the study confirms that such ADCs are only in preclinical or discovery stage of development. In addition, the report also includes a detailed overview of the contract manufacturing market for ADCs, identifying organisations with capabilities in various stages of ADC development.
The 145 page report, titled “Antibody Drug Conjugates Market, 2013-2023”, is the first comprehensive analysis of its kind in the ADC market. Key topics covered in the report are:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at email@example.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry